We pioneered the first multi-omic clinical test for coronary heart disease (CHD),
integrating epigenetics, genetics, and artificial intelligence to deliver scalable,
precise, and personalized cardiovascular solutions that improve lives.
Cardio Diagnostics was founded in 2017 by Dr. Meesha Dogan, our Chief Executive Officer, and Dr. Rob Philibert, our Chief Medical Officer. But the seeds of our innovation were planted long before then. 15 years before that, their pioneering work in epigenetics began, followed by the groundbreaking application of artificial intelligence. These early pursuits converged in the invention of our core technology, developed in collaboration with Dr. Tim Dogan, our Chief Technology Officer and the first official team member at Cardio Diagnostics.
From day one, our founders shared a bold vision: that precision cardiovascular medicine, powered by the combination of epigenetics and artificial intelligence, could transform how cardiovascular disease is detected, managed, and ultimately prevented.
For over a century, cardiovascular disease has been the world’s leading cause of death. Yet, despite this persistent threat, clinical care has largely relied on outdated, indirect biomarkers and one-size-fits-all tools that are expensive and difficult to scale. We knew there had to be a better way, and we felt a deep personal commitment to finding it. So, we built one. By harnessing the power of epigenetics, genetics, and AI, we created a new kind of technology platform - one that turns a simple blood sample into a scalable, actionable clinical tool. Our tests empower providers with insights at multiple stages of cardiovascular care, while also engaging healthcare stakeholders beyond the clinic, such as payers and employers, who play a vital role in decision-making.
Because real change requires a system-wide approach, we designed a suite of solutions tailored to both clinical and non-clinical decision-makers, arming them with the information they need to make more confident, informed choices every day. At Cardio Diagnostics, our focus is on making deliberate changes to how cardiovascular care is delivered and what that means for long-term outcomes.
We envision a healthcare system that no longer waits for a heart attack to act. A world where:
Our team includes pioneers in epigenetics and AI, world-class scientists, clinicians, and technologists with deep expertise in cardiovascular medicine, molecular biology, and artificial intelligence.
We integrate our patented and proprietary epigenetic, genetic and artificial intelligence technologies to decode molecular signals that traditional tests miss. This allows us to uncover disease processes earlier and more precisely than ever before.
We go beyond proxy biomarkers. Our technology interprets DNA methylation and genetic variations to identify dynamic biological changes, enabling earlier detection and precision intervention in cardiovascular care.
Our tests integrate seamlessly into existing clinical workflows, requiring minimal training and no additional equipment. This accessibility ensures that precision cardiovascular care can reach more patients than ever before.
